What were the main drivers behind the increase in Ecolab's net sales and profitability?

The increase in net sales and profitability was primarily driven by strong organic sales growth across most segments, particularly Global Institutional & Specialty and Global Pest Elimination. This was complemented by effective pricing strategies and reduced supply chain costs, which led to a significant improvement in gross margins. Operational efficiencies and the successful management of restructuring activities also contributed to the enhanced profitability.

How did the divestiture of the global surgical solutions business impact the financial results?

The global surgical solutions business was classified as 'held for sale' in the second quarter of 2024, with its assets and liabilities presented separately. Ecolab completed the sale of this business on August 1, 2024. While the business's operating results were still included in the financial statements for the second quarter, the sale is expected to contribute a pre-tax gain. The company anticipates this divestiture will streamline its portfolio and focus resources on core growth areas.

What is the outlook for Ecolab's restructuring and cost-saving initiatives?

Ecolab is making progress on its restructuring efforts. The 'Combined Program' related to cost savings in Europe and other regions is nearing completion. Additionally, the company announced the 'One Ecolab' initiative, which includes a new restructuring plan to leverage digital technologies and establish global centers of excellence. This initiative is expected to incur costs of $175 million in restructuring and $50 million in special charges by 2027, with anticipated savings of $140 million by the same year.

How is Ecolab managing its debt and liquidity?

Ecolab maintains a healthy financial position with total debt decreasing to $7.5 billion as of June 30, 2024, from $8.2 billion at the end of 2023. The company has a $2.0 billion revolving credit facility and no outstanding commercial paper as of the reporting date. Cash flow from operations remains strong, providing ample liquidity to fund operations, investments, and shareholder returns, including dividends and share repurchases.

ECL 10-Q Quarterly Report Q2 FY2024 — Revenue, Net Income, EPS

Summary

Ecolab Inc. (ECL) reported strong financial results for the second quarter and first six months of 2024, demonstrating significant year-over-year growth in net sales and net income. Net sales increased by 3% to $3,985.8 million in the second quarter and 4% to $7,737.7 million for the first six months, driven by robust organic sales growth across key segments, particularly Global Institutional & Specialty and Global Pest Elimination. The company also saw a substantial increase in operating income, up 36% to $656.9 million for the quarter, reflecting improved gross margins due to lower supply chain costs and effective pricing strategies. The company successfully managed its cost of sales, leading to a notable improvement in gross margin to 43.8% in the second quarter of 2024, up from 39.4% in the prior year. Net income attributable to Ecolab surged by 49% to $490.9 million ($1.71 per diluted share) for the second quarter. This performance was bolstered by strategic initiatives and operational efficiencies, despite some ongoing restructuring costs. Ecolab also completed the sale of its global surgical solutions business on August 1, 2024, which is expected to result in a pre-tax gain.

Financial Highlights

53 data points

Beta

Revenue

$3.99B

0.4% Gross Margin

Net Income

$490.90M

0.1% Net Margin

EPS (Diluted)

$1.71

Total Assets

$21.46B

Cash & Equivalents

$384.00M

Free Cash Flow

$414.20M

Financial Statements

Beta

Revenue	$3.99B
Cost of Revenue	$2.24B
Gross Profit	$1.74B
SG&A Expenses	$1.08B
Operating Income	$656.90M
Interest Expense	$80.20M
Net Income	$490.90M
EPS (Basic)	$1.72
EPS (Diluted)	$1.71
Shares Outstanding (Basic)	284.60M
Shares Outstanding (Diluted)	287.00M

Key Highlights

1Net sales increased by 3% to $3,985.8 million in Q2 2024 and 4% to $7,737.7 million in H1 2024, driven by strong organic sales growth.
2Operating income rose significantly by 36% to $656.9 million in Q2 2024, indicating improved operational efficiency and profitability.
3Gross margin improved to 43.8% in Q2 2024, up from 39.4% in Q2 2023, attributed to lower supply chain costs and effective pricing.
4Net income attributable to Ecolab grew by 49% to $490.9 million in Q2 2024, with diluted EPS rising to $1.71.
5The company continues to manage its restructuring and integration costs, with the "Combined Program" nearing completion and progress made on the "One Ecolab" initiative.
6Ecolab completed the sale of its global surgical solutions business on August 1, 2024, following its classification as 'held for sale' in Q2 2024.
7Cash flow from operations increased by $488.9 million in H1 2024 compared to H1 2023, demonstrating strong operational cash generation.

ECOLAB INC. Quarterly Report for Q2 Ended Jun 30, 2024

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions